Black Diamond Gets $85M for Cancer Drugs R&D and New Cambridge HQ

When Black Diamond Therapeutics emerged from stealth mode last month with $20 million in backing and a handful of preclinical cancer drugs, the company signaled that another financing was in the works for 2019. That day is here.